Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 amp |
| Therapy | Palbociclib + Quizartinib |
| Indication/Tumor Type | leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 amp | leukemia | sensitive | Palbociclib + Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) and Ibrance (palbociclib) synergistically inhibited viability and proliferation of a leukemia cell line with FLT3 amplification in culture (PMID: 41436723). | 41436723 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41436723) | Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. | Full reference... |